Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.1% Eye Drops as Prophylactic Treatment After Cataract Surgery in Elderly Patients at High Risk of Ocular Surface Failure
2020-001720-33Phase 4Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Feb 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of cyclosporine in dry eye syndrome (DED) and ocular surface disease (OSD) (4 arms), sponsored by Università Campus Bio-Medico di Roma. Primary endpoints: Ocular discomfort signs and symptoms and Inflammatory biomarkers on the ocular surface. Started Feb 2021; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)ocular surface disease (OSD)
Beyond the preview
Go deeper on 2020-001720-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001720-33.